USP To Discusss Methodology Behind Model Formulary Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
The group willl review its proposal on drug categories and classes for Medicare plans and hear comment from PBMs and other stakeholders during an Aug. 27 meeting.
You may also be interested in...
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.
House Appropriations Subcommittee Plans FDA Hearing July 26
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.
Second Quarter Earnings Season Heats Up
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.